According to GlobalData’s medical device pipeline database, 64 Artificial Pancreas devices are in various stages of development globally. GlobalData’s report Artificial pancreas provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 30 are in active development, while the remaining 34 are in an inactive stage of development. There are 16 products in the early stages of development, and the remaining 14 are in the late stages of development.
Diabetes care devices are used in the treatment and management of diabetes. An artificial pancreas (AP) is a device that automatically monitors blood sugar levels and delivers insulin when needed. An AP system consists of three main parts: A continuous glucose monitor (CGM) that measures blood sugar levels every few minutes. An insulin pump that delivers insulin automatically. A computer that connects the CGM and insulin pump and uses algorithms to determine how much insulin to deliver.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Artificial Pancreas pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Artificial Pancreas devices. Overall, most of these Artificial Pancreas pipeline devices are being developed by private entities.
Key players involved in the active development of Artificial Pancreas include University of Cambridge, Kailian Medical Technology, Medtronic, University of California Santa Barbara, Beta Bionics, MicroTech Medical, Miromatrix Medical, Modular Medical, Pacific Diabetes Technologies and Pancreum.
For a complete picture of the developmental pipeline for Artificial Pancreas devices, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
